Testosterone replacement in women: an indication with evidence and a lot of fad around it
Outside of a specific and well-studied use, hypoactive sexual desire in postmenopause, testosterone in women lacks evidence, and the market of hormonal optimization and pellets promises what the trials do not show. What is safe, and what is fad.
The right question: for what, and not just whether
Testosterone is a normal female androgen; the question is not having it, but for which outcome there is proof.
Testosterone is not an exclusively male hormone. It is produced by a woman's ovaries and adrenals and declines gradually with age, without an abrupt drop at menopause. Recognizing this is the starting point, but it does not answer the clinical question that matters.
The right question is not whether a woman has testosterone, but for which outcome replacement has evidence. This is where two worlds separate: a narrow, well-studied use, and a broad market of hormonal optimization, energy, and anti-aging that promises what the trials do not show.
This article situates testosterone replacement in women by the evidence for each outcome, and distinguishes what is safe from what is fad.
The only indication with evidence: hypoactive sexual desire in postmenopause
There is one use that the evidence supports, and it is specific and well defined.
There is one indication, and only one, supported by good-level evidence. The global expert consensus concluded that the only evidence-based application of testosterone in women is hypoactive sexual desire disorder in postmenopause, using doses that restore testosterone to the premenopausal physiological range (Davis et al., 2019).
The foundation is solid for this outcome. The meta-analysis of randomized trials showed improvement in sexual function, desire, arousal, and satisfaction in postmenopausal women (Islam et al., 2019), and the randomized APHRODITE trial had already demonstrated this benefit with the transdermal patch (Davis et al., 2008). The practice guideline operationalizes the approach: diagnose the disorder, use the transdermal route, maintain the physiological level, and treat for a limited time with reassessment (Parish et al., 2021).
Where there is no evidence: energy, mood, muscle, cognition, bone
Outside the sexual outcome, the claimed benefit does not appear in the trials.
This is where the market narrative detaches from science. The same meta-analysis that confirmed the sexual benefit found no benefit of testosterone for well-being, mood, cognition, bone density, or body composition in women (Islam et al., 2019). The gain, when it exists, is in the sexual domain, and not in the generic promise of vigor and vitality.
The guidelines follow this reading. The Endocrine Society, in its reappraisal, recommends against the generalized use of androgen in women for indications without evidence, precisely to contain the extrapolation (Wierman et al., 2014). In other words, testosterone for energy, focus, weight loss, or anti-aging in women is the classic example of an indication that marketing created and evidence does not support.
| Outcome | Evidence of benefit |
|---|---|
| Sexual function and desire in postmenopause | Yes, in randomized trials |
| Well-being and mood | Not demonstrated |
| Cognition | Not demonstrated |
| Bone density | Not demonstrated |
| Body composition and muscle | Not demonstrated |
| Energy and anti-aging | No basis |
Safety: what is known and what is not known
Short term reassuring with a physiological dose; long term still open.
In the short term, up to about two years and with physiological transdermal doses, the profile is reassuring: the most common adverse effect is mild, acne and increased hair, with no serious harm demonstrated (Islam et al., 2019). This safety is, however, conditional on the correct dose and route.
What is not known weighs as much as what is known. Long-term safety, especially the breast and the cardiovascular system, is not established (Davis et al., 2019). The oral route has an unfavorable effect on lipids and should be avoided; the transdermal route is preferred. And supraphysiological doses, common in implants and high-dose compounding, cause virilization, with effects that may be irreversible, such as deepening of the voice and clitoral enlargement, in addition to lipid worsening.
The practical problem: dose, route, and product
Without an approved female product, dose precision becomes the fragile point.
There is a concrete obstacle in Brazil and in most countries: there is no testosterone product approved for women. This pushes practice toward the off-label use of male formulations at a fraction of the dose or toward compounding, which turns dose precision into the main fragile point (Davis et al., 2019).
It is in this vacuum that the implants and pellets sold as hormonal optimization thrive, delivering supraphysiological and poorly controllable doses, exactly the opposite of what the evidence recommends. The correct approach measures total testosterone to keep the patient within the female physiological range, avoids the supraphysiological, and treats for a limited time, with reassessment of benefit and effects (Parish et al., 2021).
Synthesis: a narrow indication, a lot of fad around it
The evidence supports a specific use; the rest is optimization without basis.
Putting it all together: the evidence supports testosterone in women for a single outcome, hypoactive sexual desire in postmenopause, properly diagnosed, by the transdermal route, at a physiological dose, monitored and for a limited time (Davis et al., 2019, Parish et al., 2021). For energy, mood, muscle, cognition, and bone, the benefit does not appear in the trials (Islam et al., 2019).
The fad lives in the distance between this narrow indication and the broad promise of hormonal optimization. Selling testosterone as a vitality and anti-aging solution for women, especially through high-dose pellets, is to offer what the evidence does not show and to expose the patient to virilization and to unknown long-term risks.
The approach that holds up is sober: diagnose the desire disorder with the criterion of distress and low desire, exclude other causes, individualize, dose physiologically, follow up, and resist the optimization framing. Replacement is not the same as optimizing, and a hot market is not the same as evidence.
| Dimension | Indication with evidence | Optimization and pellet use |
|---|---|---|
| Outcome | Hypoactive sexual desire in postmenopause | Energy, mood, muscle, anti-aging |
| Evidence | Randomized trials and meta-analysis | Absent for these outcomes |
| Route and dose | Transdermal, physiological | Implants and pellets, supraphysiological |
| Risk | Mild (acne, hair) in the short term | Virilization, partly irreversible; lipids; long term uncertain |
| Verdict | Specific and monitored use | Fad, not recommended |
Why this matters for your care
This article follows the library's line: delimit the indication with evidence and name the fad, with rigor. Testosterone in women is a matter of medical prescription and follow-up; there is no approved female product in most countries, and pellet optimization extrapolates beyond the evidence. To organize symptoms, history, and exams before discussing management, the Functional Self-Assessment helps, and the Library gathers the other notes. Educational content; it does not replace individual medical evaluation and does not constitute a prescription.
References
- Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. Journal of Clinical Endocrinology & Metabolism. 2019. doi:10.1210/jc.2019-01603
- Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology. 2019. doi:10.1016/S2213-8587(19)30189-5
- Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen (APHRODITE). New England Journal of Medicine. 2008. doi:10.1056/NEJMoa0707302
- Parish SJ, Simon JA, Davis SR, et al. ISSWSH clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. Climacteric. 2021. doi:10.1080/13697137.2021.1891773
- Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2014. doi:10.1210/jc.2014-2260
Educational and scientific content. It does not constitute diagnosis, prescription or individual clinical guidance, and does not replace a medical consultation. Management decisions must be individualized by a physician.